Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
22 April, 2018 08:22 IST
Cipla receives final approval for generic Viread tablets
Source: IRIS | 29 Jan, 2018, 10.08AM
Comments  |  Post Comment

Cipla, a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients, announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Tenofovir Disoproxil Fumarate Tablets, 300mg, from the United States Food and Drug Administration (USFDA) to market a generic version of Gilead Sciences' Viread Tablets, 300mg.
 
Cipla's Tenofovir Disoproxil Fumarate Tablets, 300mg, are AB-rated generic equivalents of Gilead Sciences' Viread Tablets, 300mg, and are indicated in combination with other antiretroviral (ARV) agents for the treatment of HIV -1 infection in adults and paediatric patients 12 years of age and older. Cipla is excited to add this important antiretroviral product to its growing portfolio of ARVs in the U.S.

The product will be available for commercial shipment in the U.S. immediately. Viread Tablets, 300mg, had U.S. sales of approximately USD 72SM for the 12-month period ending November 2017, as reported by IMS Health.

Shares of the company gained Rs 4.25, or 0.68%, to trade at Rs 625.55. The total volume of shares traded was 11,963 at the BSE (9.59 a.m., Monday).



Cipla Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
Welspun Corp bags contract to supply water pipes in MENA region - 20-Apr-2018 10:17
TVS Motor Company launches TVS XL100 Heavy Duty 'i-Touch Start' - 20-Apr-2018 10:14
Yes Bank receives RBI approval to open overseas offices - 20-Apr-2018 10:07
Glenmark Pharma gets final nod for Clobetasol Propionate solution - 20-Apr-2018 10:03
TCS Q4 earnings grow 5.7% sequentially to Rs 69.04 bn - 20-Apr-2018 10:00
Prism Cement is now Prism Johnson - 19-Apr-2018 15:51
NACL Ind enters into strategic alliance with BioWorks - 19-Apr-2018 15:25
Ramco Systems partners with L3 MAS - 19-Apr-2018 15:21
MCX inks pact with Northern India Textiles Mills' Association - 19-Apr-2018 15:16
BP and Reliance sanction second phase of integrated KG D6 development - 19-Apr-2018 13:45
IndusInd Bank Q4 profit grows 27% to Rs 9.53 bn - 19-Apr-2018 13:40
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer